Cargando…
DNA–Polyelectrolyte Composite Responsive Microparticles for Versatile Chemotherapeutics Cleaning
Drug therapy is among the most widely used methods in disease treatment. However, there remains a trade-off problem between drug dosage and toxicity. Blood purification by adsorption of excessive drugs during clinical treatment could be a solution for enhancing therapeutic efficacy while maintaining...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AAAS
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017331/ https://www.ncbi.nlm.nih.gov/pubmed/36939415 http://dx.doi.org/10.34133/research.0083 |
Sumario: | Drug therapy is among the most widely used methods in disease treatment. However, there remains a trade-off problem between drug dosage and toxicity. Blood purification by adsorption of excessive drugs during clinical treatment could be a solution for enhancing therapeutic efficacy while maintaining normal body function. Here, inspired by the intrinsic action mechanism of chemotherapeutic agents in targeting DNA in the cell nucleus, we present DNA–polyelectrolyte composite responsive microparticles for chemotherapeutics cleaning. The presence of DNA in the microparticles enabled the adsorption of multiple common chemotherapy drugs. Moreover, the microparticles are endowed with a porous structure and a photothermal-responsive ability, both of which contribute to improved adsorption by enhancing the contact of the microparticles with the drug solution. On the basis of that, the microparticles are integrated into a herringbone-structured microfluidic chip. The fluid mixing capacity and the enhanced drug cleaning efficiency of the microfluidic platform are validated on-chip. These results indicate the value of the DNA–polyelectrolyte composite responsive microparticles for drug capture and blood purification. We believe the microparticle-integrated microfluidic platform could provide a solution for settling the dosage–toxicity trade-off problems in chemotherapy. |
---|